Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Tracking Quality of Life During Prostate Cancer Treatment
Clinical Breakthroughs

Tracking Quality of Life During Prostate Cancer Treatment

By Anna WilliamsApr 12, 2018
Share
Facebook Twitter Email
Alicia Morgans, M.D., Hematology/Oncology photos by Susan Urmy
Alicia Morgans, MD, MPH, associate professor of Medicine in the Division of Hematology and Oncology, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was the first author of the study.

Patients with advanced prostate cancer who received more intensive treatment experienced worse quality of life three months after treatment, but a better quality of life in the long term, compared to those on standard therapy, according to a new Northwestern Medicine study.

The findings were published in the Journal of Clinical Oncology.

“Treatment of prostate cancer is far more than just treating a cancer — it’s treating a person,” said first author Alicia Morgans, MD, MPH, associate professor of Medicine in the Division of Hematology and Oncology, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “That means we need to truly understand what men with prostate cancer experience — both due to the disease and due to the treatments we prescribe. If we don’t specifically ask questions about quality of life in our studies, we won’t have be able to support men and their families as they go through treatment.”

Prostate cancer is one of the most commonly diagnosed cancers in American men. For patients with an advanced form of the disease called metastatic hormone-sensitive prostate cancer (mHSPC), hormone therapy has long been the backbone of treatment.

More recently, a landmark clinical trial called E3805 demontrated that patients with mHSPC on hormone therapy who also receive a chemotherapy drug called docetaxel live significantly longer than those who undergo hormone therapy alone.

But it was not known how quality of life might be affected in men receiving docetaxel and hormone therapy, versus those receiving the standard treatment alone. Understanding quality of life in patients with prostate cancer is especially important, the authors note, since metastatic prostate cancer is incurable and commonly affects older men with comorbidities.

In the current study, patients in the E3805 clinical trial randomized to each treatment group also completed quality of life assessments. The 790 participants reported measures of quality of life — including physical, functional and emotional well-being — at baseline and at three-month intervals for up to a year after treatment.

The investigators found that at three months, patients who received chemotherapy in addition to hormone therapy reported significantly worse quality of life. However, at one year, the group reported significantly higher quality of life measures, compared to those who received hormone therapy alone.

“In other words, paying a bigger price up front is probably worth it in the long run, for the right patients,” Morgans said.

The authors note that the findings from the study — the first comparison of quality of life in this population — will be critical in helping patients and providers make more informed decisions about treatment for advanced prostate cancer.

In the trial, the benefit of more intensive treatment appeared to be biggest for patients with high-volume disease — a larger amount of metastatic prostate cancer — although this is still being confirmed in additional clinical trials, Morgans added.

The study was also co-authored by Maha Hussain, MD, deputy director of the Lurie Cancer Center and the Genevieve E. Teuton Professor of Medicine — who was also a co-author of the original E3805 publications and subsequent analyses — and by David Cella, PhD, the Ralph Seal Paffenbarger Professor and chair of Medical Social Sciences. Cella is also director of the Center for Patient-Centered Outcomes at the Institute for Public Health and Medicine, and the associate director for Cancer Prevention and Control Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The study was supported by the National Cancer Institute of the National Institutes of Health under the following award numbers: CA180820, CA180794, CA180888, CA180847, CA180867, CA180799, CA189859, CA180802, and CA180853. It was also sponsored by Sanofi via a grant to Eastern Cooperative Oncology Group-American College of Radiology Imaging Network.

Cancer Patient Care Research Urology
Share. Facebook Twitter Email

Related Posts

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

Comments are closed.

Latest News

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.